Liquidia Sues UTC Seeking Patent Damages for Tyvaso DPI Drug (1)

Liquidia Corp. sued United Therapeutics Corp. for a share of revenue from its Tyvaso DPI, alleging that a dry-powder inhalation variation of the blockbuster lung-disease drug infringes its patent.

UTC’s Tyvaso DPI infringes Liquidia’s US Patent No. 10,898,494, which covers a method for using treprostinil powder to treat high blood pressure in the lungs, according to a complaint filed Monday in the US District Court for the Middle District of North Carolina. The patent expires in May 2037, the suit said.

Liquidia seeks lost profits and royalties for sales of Tyvaso DPI, the suit said. Tyvaso DPI had sales ...